文献速递淋巴瘤

非霍奇金淋巴瘤一线治疗中利妥昔单抗由静脉转为皮下给药的安全性:MabRella研究西班牙人群

Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.
PubMed 文献 · Br J Haematol · 2019-10-01

MabRella是一项IIIb期试验,评估非霍奇金淋巴瘤(DLBCL和FL)一线诱导/维持治疗中由静脉转为皮下利妥昔单抗的安全性,重点为给药相关反应(ARR)。

要点

  • 皮下利妥昔单抗转换未发现新的安全性问题

核心结论

  • 一线治疗中由静脉转为皮下利妥昔单抗未出现新的安全性问题,并维持疗效,患者满意度和生活质量改善。

研究设计与样本

  • MabRella为IIIb期试验,西班牙人群共140例,其中DLBCL 29例、FL 111例。
  • 患者接受皮下利妥昔单抗联合标准化疗诱导4-7周期,和/或FL每2个月维持单药治疗6-12周期。

主要发现

  • 利妥昔单抗给药满意度问卷显示总体满意度改善,EuroQoL-5D显示诱导/维持结束时生活质量感知良好。

临床怎么用

  • 对于适合的DLBCL或FL患者,可考虑在一线诱导/维持治疗中由静脉转为皮下利妥昔单抗。
  • 皮下给药时需关注给药相关反应,尤其是注射部位反应,但3级事件比例较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rituximab is a standard treatment for non-Hodgkin diffuse large B-cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration-related reactions (ARRs). MabRella was a phase IIIb trial to assess the safety of switching from intravenous to subcutaneous administration of rituximab during first-line induction/maintenance for DLBCL or FL, focusing on ARRs. Efficacy, satisfaction and quality of life were also assessed. Patients received subcutaneous rituximab plus standard induction chemotherapy for DLBCL or FL for 4-7 cycles, and/or every 2 months maintenance monotherapy for FL for 6-12 cycles. The study included 140 patients: DLBCL, n = 29; FL, n = 111. Ninety-five percent of patients experienced adverse events, reaching grade ≥3 in 38·6% and were serious in 30·0%. AARs occurred in 48·6%, mostly (84·9%) at the injection site, with only 2·1% of patients reaching grade 3. The end-of-induction complete/unconfirmed complete response rate was 69·6%. After a median follow-up of 33·5 months, median disease-/event-/progression-free and overall survivals were not attained. The Rituximab Administration Satisfaction Questionnaire showed improvements in overall satisfaction and the EuroQoL-5D a good quality-of-life perception at induction/maintenance end. Therefore, switching to subcutaneous rituximab showed no new safety issues and maintained efficacy with improved satisfaction and quality of life.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. García-Muñoz R, Quero C, Pérez-Persona E, et al. Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol. 2019. PMID: 31573078. doi:10.1111/bjh.16227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。